A groundbreaking study spearheaded by researchers at Dana-Farber Cancer Institute in collaboration with the Broad Institute of MIT and Harvard has unveiled a novel genomic risk assessment tool that promises to revolutionize how multiple myeloma (MM) is understood, detected, and potentially intercepted. This innovative metric, aptly named the MM-like score, leverages whole-genome sequencing data to trace the mutational landscape of multiple myeloma from its earliest precancerous stages through to full-blown malignancy, offering an unprecedented window into the disease’s evolutionary trajectory.
Multiple myeloma is a devastating blood cancer originating in plasma cells, with approximately 32,000 new cases reported annually in the United States alone. The disease is typically preceded by clinically silent phases termed monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While MGUS and SMM are themselves asymptomatic, they carry an inherent risk of progressing to symptomatic and life-threatening multiple myeloma, with progression rates that vary widely among patients. High-risk SMM, in particular, exhibits a staggering 50% progression rate within two years, underscoring the critical need for precise prognostic tools that can stratify patients based on their likelihood of disease evolution.
Conventional risk models predominantly classify patients dichotomously into ‘high’ or ‘low’ risk categories based primarily on clinical parameters reflective of tumor burden, such as serum free light chains and bone marrow plasmacytosis. However, these models overlook the complex genomic architecture that underpins disease initiation and progression. The MM-like score addresses this gap by quantitatively capturing the accumulation and escalation of somatic mutations that drive the pathogenesis of multiple myeloma. It integrates genetic aberrations characterized across disease states to estimate the dynamic risk of transformation from precursor conditions to active disease.
Dr. Jean-Baptiste Alberge, PhD, co-senior author and an instructor of medicine at Dana-Farber, highlights the clinical significance of this development, emphasizing how the MM-like score enhances the prediction of disease progression in patients harboring precursor conditions. The continuous nature of this score offers a nuanced depiction of tumor evolution that transcends the simplistic binary risk stratification, reflecting the intricate temporal interplay of genetic insults that shape tumor behavior.
Underpinning this advancement is one of the most comprehensive whole-genome sequencing endeavors to date in multiple myeloma and its precursors. The collaborative effort analyzed genomic data from over 1,000 patients worldwide, including 218 with MGUS or SMM, encompassing a breadth of demographic and disease heterogeneity. This vast dataset illuminated not only the spectrum of cancer-driving mutations but also their temporal order, revealing that critical genomic alterations may emerge early in adulthood, decades before clinical diagnosis—a revelation that challenges existing paradigms about tumor latency and onset.
The study further elucidated the mutational signatures distinguishing active multiple myeloma from its asymptomatic antecedents. By dissecting the prevalence and patterns of genetic changes among different disease stages, researchers were able to pinpoint candidate genes likely instrumental in disease progression. This insight paves the way for more targeted therapeutic strategies that could intercept the disease during its nascent phases, circumventing full malignancy.
Validation of the MM-like score utilized longitudinal tumor samples from 20 patients monitored across their disease course. The findings demonstrated a compelling concordance between the score’s temporal dynamics and clinical outcomes: patients who remained stable exhibited steady MM-like scores, whereas those who progressed showed escalating scores concomitant with disease advancement. This correlation affirms the score’s potential utility as a biomarker for real-time disease monitoring and risk prediction.
One of the team’s most ambitious goals is to translate the MM-like score into a clinically accessible test leveraging liquid biopsies. This approach would circumvent the invasiveness of conventional bone marrow biopsies by analyzing circulating tumor DNA in blood, facilitating more frequent, minimally invasive surveillance of disease evolution. Such technological innovation could democratize access to precision monitoring, enabling early therapeutic interventions tailored to individual genomic risk trajectories.
Dr. Irene Ghobrial, director of the Center for Early Detection and Interception of Blood Cancers at Dana-Farber, underlines the transformative implications of integrating genomic data into clinical decision-making. Early identification of high-risk SMM patients could herald a paradigm shift toward early therapeutic interception before the onset of symptomatic disease, ultimately improving survival outcomes and quality of life.
Gad Getz, PhD, director of Cancer Genome Computational Analysis at the Broad Institute, underscores the irreplaceable value of deep whole-genome sequencing in uncovering the complex mutational origins and timing of multiple myeloma. The ability to detect subtle, yet pivotal, genomic events across a diverse patient cohort has yielded insights that were previously unattainable, highlighting the promise of advanced computational genomics in oncology.
The research also raises provocative questions about the biology of multiple myeloma initiation. The inferred timeline positing that key oncogenic mutations accumulate as early as patients’ second or third decade of life necessitates reconsideration of cancer surveillance strategies and beckons further investigation into environmental, hereditary, or biological factors contributing to early mutagenesis.
As the scientific community embraces this innovative MM-like score, future research aims to expand patient cohorts for longitudinal studies, refine the scoring algorithm with enhanced genomic markers, and integrate it with existing clinical models. Together, these efforts seek to pioneer a holistic framework for personalized risk stratification, early detection, and precision therapy in multiple myeloma—a field where early intervention could markedly alter disease trajectories.
This seminal study not only propels the understanding of multiple myeloma’s genomic evolution forward but also exemplifies the power of collaborative, cross-disciplinary research. By bridging genomic science and clinical oncology, the MM-like score has the potential to reshape patient care paradigms, heralding a new era of proactive, genome-informed management of blood cancers.
—
Subject of Research: Genomic risk stratification and disease progression in multiple myeloma
Article Title: Not explicitly stated, but inferred as “A genomic MM-like score predicts progression in multiple myeloma precursor conditions.”
News Publication Date: May 21, 2025
Web References:
Dana-Farber Cancer Institute: https://www.dana-farber.org/
Nature Genetics article: https://www.nature.com/articles/s41588-025-02196-0
References:
Original study published in Nature Genetics, May 2025
Keywords: multiple myeloma, MM-like score, genomic risk, disease progression, whole-genome sequencing, smoldering multiple myeloma, monoclonal gammopathy, cancer genomics, early detection, liquid biopsy
Tags: asymptomatic blood cancerDana-Farber Cancer Instituteevolution of multiple myelomagenomic risk assessment toolhigh-risk smoldering multiple myelomaMM-like scoremonoclonal gammopathy of undetermined significancemultiple myeloma progression riskprecancerous stages of multiple myelomaprognostic tools in cancersmoldering multiple myelomawhole genome sequencing